Inside Information according to Article 17 MAR

Ad-hoc Announcements

Archive Ad-Hoc Announcements

No Inside Information according to Article 17 MAR / Ad-hoc Announcements were issued in year 2019.

November 29, 2018 at 02:45 p.m. CET

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

/ MORE


June 3, 2018 at 06:44 p.m. CEST

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer resolves capital increase with subscription rights against cash contributions in the amount of 6.0 billion euros to finance the acquisition of Monsanto

/ MORE


April 16, 2018 at 08:10 p.m. CEST 

Temasek subscribes to capital increase and acquires approximately 3.6 percent of Bayer

/ MORE

 

 

June 30, 2017 at 09:18 a.m. CEST

Bayer expects negative earnings impact from its Brazilian Crop Science business

/ MORE


February 08, 2017 at 04:35 p.m. CET

Bayer: Phase III COMPASS study with Bayer’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early

/ MORE


 

 

November 15, 2016 at 05:48 p.m. CET

Bayer to issue mandatory convertible notes

/ MORE


September 14, 2016 at 01:17 p.m. CEST

Bayer and Monsanto to Create a Global Leader in Agriculture

/ MORE


September 6, 2016 at 00:38 a.m. CEST

Negotiations regarding Monsanto acquisition advance

/ MORE


May 23, 2016 at 07:00 a.m. CEST

Bayer Offers to Acquire Monsanto for USD 122 per Share in Cash to Create a Global Leader in Agriculture    

/ MORE


February 24, 2016 at 10:58 a.m. CET

Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG

/ MORE

 

October 1, 2015

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Covestro stock market listing: price range and gross proceeds adjusted

/ MORE


September 18, 2015

Bayer aligns organization with Life Science businesses    

/ MORE


September 4, 2015

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Bayer plans IPO for Covestro

/ MORE


 

 

September 18, 2014

Strategic corporate decision:
Bayer plans to focus entirely on Life Science businesses

/ MORE


September 18, 2014

Strategic corporate decision:
Bayer Board of Management plans to focus entirely on Life Science businesses

/ MORE


 

 

No Ad-hoc Announcements were issued in year 2013.

No Ad-hoc Announcements were issued in year 2012.

September 29, 2011

Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

/ MORE


September 6, 2011

Bayer AG: FDA has published documents for discussion at the Advisory Committee on the new drug application for Rivaroxaban

/ MORE


 

 

October 31, 2010

Bayer AG: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin

/ MORE


August 4, 2010

Bayer AG: Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study

/ MORE